Johns Hopkins Medicine news release
Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV by blocking specific enzymes the virus uses to multiply can cause metabolic complications, including weight gain and insulin resistance. Since 2015, integrase strand transfer inhibitor-based regimens have been recommended as first-line treatment. In a new Johns Hopkins Medicine study funded by the National Institutes of Health, researchers found adults with HIV who switched from protease inhibitors to integrase inhibitors were at increased risk of diabetes.
Read the full news release here.
Source : Johns Hopkins Medicine
Related HIV and Co-Infections News
-
ACTG launches landmark study evaluating treatments for depressive disorders with or without mild neurocognitive disorder among people living with HIV
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.